The two ingredients of BromAc attack biofilm in fundamentally different ways. N-acetylcysteine, or NAC, is the N-acetylated derivative of the amino acid L-cysteine, long used clinically as a mucolytic and as the antidote for paracetamol poisoning. Its antibiofilm power comes from a free thiol group that chemically reduces disulfide crosslinks holding together the polysaccharide and protein strands of the biofilm’s extracellular matrix. Bromelain, by contrast, is a cocktail of cysteine proteases extracted from pineapple stem, already used as an anti-inflammatory and wound-debridement agent with regulatory precedent in enzymatic burn treatment. Its proteolytic activity cleaves the peptide bonds of the protein scaffold, including fibrin and collagen, that stabilises biofilm architecture. Because biofilm matrices contain both polysaccharide-stabilised and proteinaceous components in varying proportions, the review’s authors argue that a dual-action agent targeting both simultaneously is mechanistically rational in a way single agents cannot be.

The scale of the clinical problem gives this mechanistic appeal real urgency. Current management of prosthetic joint infection relies on surgical debridement combined with antibiotics and implant retention, a strategy known as DAIR, or on two-stage revision in which the prosthesis is removed, an antibiotic spacer is implanted, and reimplantation follows months later. A recent meta-analysis cited in the review found that DAIR procedures fail in roughly 36 percent of cases on average, with failure rates climbing from about 34 percent in acute infections to nearly 74 percent in late chronic infections. Two-stage revision achieves better outcomes, typically between 54 and 100 percent success, but demands multiple surgeries, prolonged disability, and substantial cost. The fundamental limitation is that mechanical debridement with curettes and pulse lavage cannot reliably strip biofilm from prosthetic surfaces, while systemically delivered antibiotics penetrate the matrix poorly.

The laboratory evidence for each component of BromAc is instructive. A landmark 2013 study by Drago and colleagues tested NAC against Staphylococcus aureus and Pseudomonas aeruginosa biofilms grown on smooth polyethylene and sand-blasted titanium discs, the very materials used in hip and knee prostheses. NAC achieved roughly 50 percent biofilm reduction on polyethylene but only about 20 percent on titanium at minimum inhibitory concentrations after three hours of exposure. Studies outside orthopaedics suggest higher concentrations can do more: in staphylococcal isolates from chronic rhinosinusitis, NAC at eight times the minimum inhibitory concentration eradicated biofilm in 81.5 percent of isolates. Bromelain, meanwhile, reduced biofilm biomass by up to 98 percent in a wound-relevant S. aureus model supplemented with human plasma, and a 2025 study on cortical bone screws contaminated with MRSA found that bromelain powder combined with scrubbing produced the greatest reduction in adherent biomass of any tested regimen.

The pivotal proof-of-concept study for the combination came from Carter and colleagues in 2021, who tested BromAc against biofilms formed by three strains of Pseudomonas aeruginosa on surgical hernia mesh. Intriguingly, NAC alone actually enhanced growth in two of the three strains, while biofilms were more susceptible to bromelain alone. The combination overcame this limitation dramatically, achieving more than 80 percent biofilm removal, quantified by crystal violet biomass reduction, across all three strains, with corresponding one to two log reductions in adherent viable bacteria. Microscopy confirmed physical disruption of biofilm architecture with previously embedded bacteria left exposed. The strongest effects occurred at higher bromelain-to-NAC ratios, and no antagonistic interactions between the agents were observed.

Yet the review is notably candid about how far this evidence falls short of clinical readiness. The principal proof-of-concept study used hernia mesh rather than orthopaedic implants and Pseudomonas rather than the staphylococci that dominate prosthetic joint infection. It was also funded by the manufacturer of BromAc, and independent replication is lacking. More recent data showing BromAc activity against S. aureus on surgical metal clips and near-complete eradication of S. epidermidis biofilms when combined with vancomycin or rifampicin come from the sponsor and remain unpublished and unpeer-reviewed. The reviewers flag that across the preclinical literature, studies differ in pathogen, substrate, exposure time, and outcome measure, making direct comparison of efficacy figures hazardous. Crystal violet assays, moreover, measure total biomass including dead cells and residual matrix, so they evidence biofilm disaggregation rather than bacterial killing; corroborating viable-count recovery will be essential in future work.

Formulation stability poses a further, less obvious barrier. The same free thiol group that gives NAC its antibiofilm activity is susceptible to autoxidation in aqueous solution, a process accelerated by oxygen, metal ions, elevated pH, and warmth. Reported shelf lives of reconstituted NAC solutions range from a few hours at ambient temperature to 24 hours under refrigeration and light protection, and loss of free thiol translates directly into loss of biofilm-disrupting potency. Bromelain, for its part, loses proteolytic activity in solution through autodigestion. In an operating theatre, this means BromAc cannot be assumed to retain full activity if mixed in advance, and point-of-use reconstitution, preservative-free buffering, and oxygen-protective packaging would likely be required. Nothing is yet known about the pharmacokinetics of either agent inside an infected joint, including residence time, clearance, and protein binding in synovial fluid.

Safety questions specific to the joint environment loom equally large. BromAc has been administered to more than 100 patients by intratumoural and intraperitoneal injection in first-in-human and Phase III trials for pseudomyxoma peritonei, with a manageable safety profile, and across 21 preclinical animal experiments it has shown a favourable safety record via intraperitoneal, subcutaneous, intravenous, and inhaled routes. But none of these routes approximates injection into a weight-bearing joint, where cartilage, synovium, and the bone-implant interface are uniquely vulnerable to a proteolytic enzyme. The safety database for intra-articular BromAc is, as the reviewers put it, empty. Effects on cartilage integrity, synovial inflammation, and osseointegration of the implant are entirely unknown, as are the optimal NAC-to-bromelain ratio, pH, osmolality, dosing, and contact time.

To close these gaps, the authors lay out a structured preclinical programme before any first-in-human orthopaedic trial could be defensible. It begins with small-animal models using implanted titanium or polyethylene carrying established staphylococcal biofilm, with endpoints of viable bacterial recovery and histological assessment of joint tissue, followed by large-animal studies with loaded prostheses and dynamic synovial fluid sampling, ex vivo human cartilage and synovium tolerance studies, and formulation-stability testing under realistic operating-theatre conditions. Only consistent positive efficacy and acceptable safety across all four streams, ideally replicated independently of the sponsor, would justify moving to the clinic.

On present evidence, BromAc stands as a promising but unvalidated adjunct for prosthetic joint infection: mechanistically elegant, cheap relative to revision surgery, and built from two agents with long clinical histories, yet supported almost entirely by preclinical data on non-orthopaedic substrates and partly by unpublished sponsor figures. If the necessary validation succeeds, the combination could improve DAIR success rates, spare thousands of patients prosthesis removal, and potentially extend to other biofilm-associated implant infections. Until then, the reviewers conclude, any clinical use outside a properly designed and regulated trial is not justified.

Subject of Research: Preclinical evaluation of bromelain and N-acetylcysteine combination therapy for disrupting biofilms in prosthetic joint infection

Article Title: Bromelain and N-acetylcysteine (BromAc) as novel adjunctive therapy for prosthetic joint infection: a narrative review

Article References: Bromelain and N-acetylcysteine (BromAc) as novel adjunctive therapy for prosthetic joint infection: a narrative review. (n.d.). https://doi.org/10.5194/jbji-11-441-2026

Image Credits: AI Generated

DOI: 10.5194/jbji-11-441-2026

Keywords: prosthetic joint infection, biofilm, BromAc, bromelain, N-acetylcysteine, DAIR, joint arthroplasty, antibiofilm therapy, implant infection, Staphylococcus aureus, Pseudomonas aeruginosa, drug stability

Carbon dots have quietly attracted attention over the past decade for their unusual combination of properties. They are photochemically stable, biocompatible, low in toxicity, and fluorescent, which has already made them useful in cellular imaging, biosensing, and drug delivery. But what makes them especially interesting in the antibiofilm arena is their synthetic flexibility. Researchers can choose precursors and synthesis methods that deliberately install specific surface functionalities—amines for a positive charge, carboxylic acids for a negative charge, or hydrophobic domains—each of which governs how the dots interact with the complex architecture of a biofilm and the cells hidden within it. In other words, the recipe determines the weapon.

The review, written by a team led by Hadeer M. Bedair and Tamer M. Samir, categorizes synthesis strategies into top-down and bottom-up approaches, with the latter dominating current research. Hydrothermal, solvothermal, microwave-assisted, pyrolysis, and thermal decomposition methods convert small organic molecules or biomass into nanosized carbon cores through dehydration, polymerization, aromatization, and carbonization. Microwave-assisted synthesis has emerged as a standout because it heats the reaction volumetrically through dielectric heating, shrinking reaction times from hours to minutes while promoting homogeneous nucleation and often improving fluorescence and yield. Still, the method is not without drawbacks: product quality depends heavily on microwave power, reaction time, precursor composition, and solvent properties, and scale-up remains challenging because microwave penetration depth decreases as reaction volume grows—a limitation that pushes researchers toward dedicated laboratory reactors rather than domestic ovens.

When it comes to Gram-positive bacteria, the review finds that cationic design has been the dominant strategy. The cell walls of bacteria such as Staphylococcus aureus carry a net negative charge, courtesy of teichoic acids and phospholipid membranes, so positively charged dots bind electrostatically and tear membranes apart. The comparative data reveal striking differences. Quaternized carbon dots achieved complete prevention of S. aureus biofilm at 1,000 micrograms per milliliter, while polyethyleneimine–citric acid dots required 1,500 micrograms per milliliter. In contrast, spermidine-capped carbon dots achieved 81.34 percent inhibition at just 16 micrograms per milliliter, and guanidinium-based dots reduced methicillin-resistant S. aureus biofilm to near-zero levels at 20 micrograms per milliliter. The guanidinium group, capable of forming bidentate hydrogen bonds with negatively charged cell-surface components in addition to electrostatic attraction, appears to be a particularly potent motif. The message is clear: the molecular architecture of the cationic moiety matters as much as the charge itself.

Beyond brute-force electrostatics, the review highlights increasingly sophisticated smart designs. Folic acid-derived carbon dots exploit folate receptors overexpressed on many bacterial species to target infection sites, disrupting 82 percent of mature S. aureus biofilms at 1,000 micrograms per milliliter. A pH-responsive dissociable nanosystem remains inert during transit but disassembles within the acidic microenvironment of a growing biofilm, releasing both a biocidal cationic polymer and l-lysine-derived dot cores that generate intracellular reactive oxygen species, degrading the extracellular matrix and killing embedded bacteria. Perhaps most striking is a conversion strategy in which the antibiotic gentamicin sulfate was directly calcined into carbon dots, yielding a material that retained the parent drug’s active structure while gaining a positively charged surface and reactive oxygen species generation. The result: more than 99 percent destruction of S. aureus biofilms at just 80 micrograms per milliliter, with low observed drug resistance—a compelling route to repurposing existing antibiotics into multifunctional nanomaterials.

Gram-negative pathogens present a far harder problem. Their outer membrane, an asymmetric bilayer rich in lipopolysaccharide, functions as a formidable permeability barrier that blunts the electrostatic interactions so effective against Gram-positive cells. Nitrogen-doped dots that fully inhibited Bacillus subtilis biofilm at 25 milligrams per milliliter required the same high concentration to inhibit Escherichia coli, a disparity the authors attributed to the thicker lipopolysaccharide layer. Effective concentrations against Gram-negative targets in the reviewed literature span more than four orders of magnitude, from 4 micrograms per milliliter to 25,000. The most potent systems share a common feature: multiple synergistic mechanisms rather than electrostatics alone. A cobalt-nickel ferrite/silica/titania/carbon-dot nanocomposite combining photocatalysis with magnetic properties inhibited 93.92 percent of E. coli biofilm at just 15 micrograms per milliliter. An iron and nitrogen co-doped nanozyme with peroxidase-like activity achieved 73.2 percent inhibition of Hafnia alvei biofilm at 4 micrograms per milliliter by converting hydrogen peroxide into toxic hydroxyl radicals—and, in a practical demonstration, extended the shelf life of salmon by three to six days. Red-emissive dots activated by light achieved 85 percent inhibition of multidrug-resistant Acinetobacter baumannii biofilm at 150 micrograms per milliliter through photodynamic generation of reactive oxygen species, an approach particularly suited to wound and device infections where light can be applied externally.

Fungal biofilms, especially those formed by Candida species, represent a distinct clinical challenge because fungal cells are eukaryotic, making selective toxicity substantially harder to achieve. The review notes that research here remains scarce but promising. Simple dots made from Citrus limetta fruit juice achieved a modest 40 percent reduction of Candida albicans biofilm at 75 micrograms per milliliter, likely through interference with quorum sensing and initial adhesion. More sophisticated designs fared better: guanidine-functionalized red-emissive dots conjugated with amphotericin B significantly reduced C. albicans biofilm at 100 micrograms per milliliter while preserving the integrity of reconstituted human oral epithelial tissue—a crucial demonstration of selective toxicity. The magnetic-photocatalytic nanocomposite inhibited 92.35 percent of Candida tropicalis biofilm at 15 micrograms per milliliter, though its lower activity against C. albicans underscores how sharply antifungal susceptibility varies even within a single genus. In another innovative approach, red-emitting dots embedded in poly-l-lactic acid scaffolds convert near-infrared light into localized heat, achieving 60 percent inhibition of clinical Candida parapsilosis biofilms—a physical mechanism unlikely to induce resistance and readily adaptable to self-sterilizing medical devices.

Mechanistically, the review argues that no single mode of action explains carbon dot antibiofilm activity; rather, the most effective systems combine several. Electrostatic binding initiates contact with anionic bacterial surfaces and matrix components. The ultrasmall size of the dots—typically below ten nanometers—allows them to diffuse through the water channels of the extracellular matrix that exclude most conventional antibiotics, reaching persister cells in the deepest layers. Once internalized, many dots trigger intracellular reactive oxygen species, damaging proteins, lipids, and DNA while simultaneously degrading the matrix polysaccharides and extracellular DNA that hold the biofilm together. Intriguingly, some dots work without killing cells at all. Curcumin-derived dots downregulated adhesion and biofilm maturation genes in Enterococcus faecium, while tinidazole-functionalized dots suppressed fimbriae and protease genes in Porphyromonas gingivalis. Bacteria-derived dots inhibited E. coli biofilm formation without affecting planktonic growth at all, pointing to specific interference with regulatory pathways such as sulfur metabolism or cyclic di-GMP signaling. This disarming strategy, which disrupts the regulatory networks governing biofilm formation rather than the cells themselves, may exert less selective pressure for resistance—one of the most tantalizing implications of the entire field.

The authors are candid about the hurdles between laboratory promise and clinical reality. Effective concentrations vary enormously across studies, partly because testing protocols are not standardized, making direct comparisons difficult. The molecular events governing how dots traverse the Gram-negative outer membrane, and how they achieve selective toxicity against microbes without harming mammalian cells, remain poorly understood. Almost all published results come from in vitro experiments; long-term biocompatibility, biodistribution, pharmacokinetics, immunogenicity, and environmental safety in living organisms have barely been examined. Large-scale production, batch-to-batch consistency, storage stability, and regulatory approval remain unsolved. The review calls for standardized synthesis and characterization protocols, systematic structure–activity studies, testing against clinically relevant multispecies biofilms and drug-resistant isolates in realistic infection models, and eventually rigorous preclinical and clinical trials. If those challenges are met—potentially aided by artificial intelligence-assisted nanomaterial design and green synthesis—the authors believe carbon quantum dots could evolve from experimental curiosities into safe, effective platforms for the prevention, diagnosis, and treatment of biofilm-associated infections, offering a genuinely new weapon against one of medicine’s most persistent enemies.

Subject of Research: The antibiofilm activity of carbon quantum dots against bacteria and fungi

Article Title: Insights Into the Antibiofilm Activity of Carbon Quantum Dots Against a Panel of Different Microorganisms: A Review

Article References: Bedair, H. M., Hamed, M., Shoun, A. A., Mansour, F. R., Obaydo, R. H., & Samir, T. M. (2026). Insights Into the Antibiofilm Activity of Carbon Quantum Dots Against a Panel of Different Microorganisms: A Review. MicrobiologyOpen, 15(5), Article e70411. https://doi.org/10.1002/mbo3.70411

Image Credits: AI Generated

DOI: 10.1002/mbo3.70411

Keywords: carbon quantum dots, biofilms, antimicrobial resistance, nanomaterials, MRSA, reactive oxygen species, quorum sensing, Gram-negative bacteria, Candida, nanotechnology, antibiofilm therapy, photodynamic therapy